A disposable absorbent hygiene product is provided, comprising an absorbent core disposed between a liquid pervious topsheet intended to face the wearer, and a backsheet intended to face away from the wearer, wherein said absorbent core comprises a super absorbent polymer composition that comprises a) super absorbent polymer particles including a cross-linked polymer of a water soluble ethylenically unsaturated monomer containing an acidic group, at least a part of said acidic groups being neutralized; and b) a particle size-controlled antibacterial agent that comprises a chelating agent containing EDTA or an alkali metal salt thereof; a mixture of an organic acid and a silicate-based salt; and a particle size control agent.

A medical polymer device comprising a biodegradable polymer is provided, wherein the biodegradable polymer has a crystallinity of about 10% to about 80%, and preferably from about 20% to about 60%, wherein the medical polymer device comprises a small molecule organic compound which diffuses into the biodegradable polymer, the small molecule organic compound has a molecular weight of from about 100 to about 1000 Daltons, preferably from about 150 to about 500 Daltons, and more preferably from about 150 to about 250 Daltons, and the small molecule organic compound is non-evaporating or low-evaporating. The present invention also provides a method for preparing a medical polymer device according to the present invention as well as a method for modifying a medical polymer device made from a biodegradable polymer.

The present disclosure relates to methods of preparing personalized blood vessels, useful for transplantation with improved host compatibility and reduced susceptibility to thrombosis. Also provided are personalized blood vessels produced by the methods and use thereof in surgery.

Antimicrobial compositions and articles are disclosed, as well as method for preparing antimicrobial compositions. Also disclosed are method for using antimicrobial compositions and articles for preventing the formation or growth of biofilms, disrupting biofilms, reducing microorganism counts, and treating infections.

Various embodiments relate to catheter locking solutions and catheter locking therapies with use of trisodium citrate and ethyl alcohol, and in particular 4.0 to 15.0 weight/volume % trisodium citrate as an anticoagulant component and/or an antibacterial component and 15.0 to 25.0 volume/volume % ethyl alcohol as an antibacterial component. Use of the catheter locking solution and catheter locking therapy can reduce treatment failure during medical procedures that may employ catheters to supply treatment by at least significantly reducing the risks associated with bloodstream infections, catheter system malfunction, emboli formation, patient discomfort, and patient illness. These benefits can be partially due to the synergistic antibacterial effects of the trisodium citrate and ethyl alcohol in solution, generating an effective catheter locking solution with minimal concentrations of ethyl alcohol.

An injectable aqueous implant formulation, and processes for making and using the formulation, wherein the injectable aqueous implant formulation has been sterilized by gamma-ray or X-ray-irradiation and can be extruded through a tapering system and an 18 gauge (0.838 mm inner diameter) 25.4 mm long cannula with a force not exceeding 60 N, which comprises 25-45 w/w % of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 m as determined by sieving and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve, whereby the w/w ratio of nanocrystalline hydroxyapatite to collagen is from 1.8 to 4.5, which contains at least 0.05% (w/w) ascorbic acid.

An injectable aqueous implant formulation, and processes for making and using the formulation, wherein the injectable aqueous implant formulation has been sterilized by gamma-ray or X-ray-irradiation and can be extruded through a tapering system and an 18 gauge (0.838 mm inner diameter) 25.4 mm long cannula with a force not exceeding 60 N, which comprises 25-45 w/w % of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 m as determined by sieving and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve, whereby the w/w ratio of nanocrystalline hydroxyapatite to collagen is from 1.8 to 4.5, which contains at least 0.05% (w/w) ascorbic acid.

A wetness indicator composition comprising at least one pH-indicator colorant, from about 0.001% to about 75% by weight of at least one color-stabilizer, and from 0.1% to 70% by weight of at least one hardening agent, and wherein the wetness indicator has a defined and properly selected hot to cold solidification rate, hardness and melt point.

The wound dressing described herein can be used as a contact layer dressing. The wound dressing can be positioned between a wound bed and a secondary dressing. The wound dressing can include a layered construction. Each of the layers can include a bioresorbable sponge enclosed within a collagen-based film. The wound dressing can include a plurality of fluid channels that enable fluid flow from the wound bed toward the environment-face side of the wound dressing.

An absorbable metal stent includes an absorbable metal substrate; the absorbable metal substrate includes a plurality of wave-shaped annular structures and a plurality of axial connecting portions, two ends of each axial connecting portion being connected to two adjacent wave-shaped annular structures, respectively, so as to axially connect the plurality of wave-shaped annular structures; a corrosion-promoting coating is formed on each axial connecting portion, the corrosion-promoting coating containing a corrosion-promoting substance, and the corrosion-promoting substance being selected from at least one of a degradable polymer and a degradable polymer antioxidant; the corrosion-promoting coatings cause the corrosion of the axial connecting portions to occur earlier than the corrosion of the plurality of wave-shaped annular structures. The absorbable metal stent has good bending performance and may prevent the problems of secondary hyperplasia after implantation and stenosis caused thereby.